Teva Pharmaceutical Industries Cash on Hand 2010-2024 | TEVA

Teva Pharmaceutical Industries cash on hand from 2010 to 2024. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
  • Teva Pharmaceutical Industries cash on hand for the quarter ending September 30, 2024 was $3.319B, a 47.58% increase year-over-year.
  • Teva Pharmaceutical Industries cash on hand for 2023 was $3.226B, a 15.17% increase from 2022.
  • Teva Pharmaceutical Industries cash on hand for 2022 was $2.801B, a 29.38% increase from 2021.
  • Teva Pharmaceutical Industries cash on hand for 2021 was $2.165B, a 0.55% decline from 2020.
Teva Pharmaceutical Industries Annual Cash on Hand
(Millions of US $)
2023 $3,226
2022 $2,801
2021 $2,165
2020 $2,177
2019 $1,975
2018 $1,782
2017 $963
2016 $988
2015 $6,946
2014 $2,226
2013 $1,038
2012 $2,879
2011 $1,096
2010 $1,248
2009 $2,248
Teva Pharmaceutical Industries Quarterly Cash on Hand
(Millions of US $)
2024-09-30 $3,319
2024-06-30 $2,258
2024-03-31 $2,991
2023-12-31 $3,226
2023-09-30 $2,249
2023-06-30 $2,669
2023-03-31 $2,143
2022-12-31 $2,801
2022-09-30 $2,225
2022-06-30 $2,058
2022-03-31 $2,175
2021-12-31 $2,165
2021-09-30 $2,045
2021-06-30 $2,436
2021-03-31 $1,743
2020-12-31 $2,177
2020-09-30 $1,827
2020-06-30 $2,402
2020-03-31 $1,804
2019-12-31 $1,975
2019-09-30 $1,241
2019-06-30 $2,165
2019-03-31 $1,973
2018-12-31 $1,782
2018-09-30 $1,875
2018-06-30 $1,861
2018-03-31 $1,418
2017-12-31 $963
2017-09-30 $680
2017-06-30 $599
2017-03-31 $900
2016-12-31 $988
2016-09-30 $2,614
2016-06-30 $6,984
2016-03-31 $5,964
2015-12-31 $6,946
2015-09-30 $928
2015-06-30 $1,068
2015-03-31 $3,396
2014-12-31 $2,226
2014-09-30 $1,473
2014-06-30 $949
2014-03-31 $901
2013-12-31 $1,038
2013-09-30 $1,148
2013-06-30 $1,245
2013-03-31 $1,394
2012-12-31 $2,879
2012-09-30 $1,432
2012-06-30 $1,188
2012-03-31 $1,062
2011-12-31 $1,096
2011-09-30 $1,123
2011-06-30 $1,157
2011-03-31 $748
2010-12-31 $1,248
2010-09-30 $956
2010-06-30 $4,878
2010-03-31 $2,693
2009-12-31 $2,248
2009-09-30 $1,778
2009-06-30 $1,803
2009-03-31 $2,400
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $19.044B $15.846B
Teva Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets both branded and generic drugs, as well as active pharmaceutical ingredients in North America, Europe, Latin America, India, and Israel. Teva's generic product portfolio includes tablets, capsules, liquids, ointments, creams, liquids, injectables, and inhalants. The company's branded products include Copaxone, Austedo, respiratory products like ProAir and Qvar and Ajovy. Teva operates through three segments, North America, Europe and International Markets, each of which includes generics, specialty and over-the-counter products. Teva acquired Allergan's generics business Actavis Generics. The company also acquired Allergan's Anda Inc. Teva acquired Auspex Pharmaceuticals and Barr. Teva has strengthened its position in Europe through its acquisition of Germany's second largest generics producer, ratiopharm.
Stock Name Country Market Cap PE Ratio
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00